Literature DB >> 16405668

Prevalence of hepatitis C virus infection in cases of B-cell lymphoma in Japan.

M Takeshita1, H Sakai, S Okamura, K Higaki, Y Oshiro, N Uike, I Yamamoto, K Shimamatsu, T Muranaka.   

Abstract

AIMS: To determine the prevalence of hepatitis C virus (HCV) infection in B-cell lymphoma in Japan. HCV infection and type II (monoclonal IgM) cryoglobulinaemia (CG) may be involved in the pathogenesis of low-grade B-cell lymphoma (ML) in southern Europe. METHODS AND
RESULTS: Forty-five (11.3%) of 400 B-cell ML cases were HCV antibody (Ab) positive, which was significantly (P < 0.01) higher than the blood donors (2.5%). Among them, 28 diffuse large B-cell lymphoma (DLBCL) cases were included. In the primary sites, 10 (47.6%) of 21 splenic DLBCL and seven (23.3%) of 30 gastric DLBCL were HCV Ab positive, which were significantly (P < 0.05) higher than the myeloma cases (4.9%). HCV infection was rarely (4.2%) detected in 24 lymphoplasmacytic and salivary gland low-grade B-cell ML cases. Type II CG was detected in one myeloma case (3.5%) of 29 HCV+ B-cell ML. By real-time polymerase chain reaction, HCV RNA was detected in fresh tumour tissues of all 11 B-cell ML cases examined. Lymphoma cells were positive for the envelope HCV non-structural (NS)3 and envelope (E2) proteins in six of eight examined B-cell ML cases.
CONCLUSIONS: The rare incidence of type II CG is characteristic of Japanese HCV+ ML patients and may influence the low incidence of low-grade B-cell ML. HCV infection may play a role in lymphomagenesis of splenic and gastric DLBCL.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16405668     DOI: 10.1111/j.1365-2559.2005.02311.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  11 in total

1.  HCV non-structural protein 3 and HCV RNA genome in non-Hodgkin lymphoma and transition of the serum HCV RNA level: a retrospective analysis in one institution.

Authors:  Souichi Shiratori; Yutaka Tsutsumi; Takahito Kawamura; Kazuhiro Kudo; Norihiko Shimoyama; Nobuo Masauzi; Junji Tanaka; Masahiro Asaka; Masahiro Imamura
Journal:  Int J Hematol       Date:  2008-03-06       Impact factor: 2.490

2.  Risk of malignant lymphoma following viral hepatitis infection.

Authors:  Pierluigi Cocco; Giovanna Piras; Maria Monne; Antonella Uras; Attilio Gabbas; Maria G Ennas; Angelo Palmas; Marco Murineddu; Stefania Collu; Massimo Melis; Marco Rais; Pierfelice Todde; Maria G Cabras; Emanuele Angelucci; Giovannino Massarelli; Alexandra Nieters
Journal:  Int J Hematol       Date:  2008-05-01       Impact factor: 2.490

Review 3.  Extrahepatic cancers and chronic HCV infection.

Authors:  Stanislas Pol; Anaïs Vallet-Pichard; Olivier Hermine
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-01-17       Impact factor: 46.802

Review 4.  Possible association between hepatitis C virus and malignancies different from hepatocellular carcinoma: A systematic review.

Authors:  Sirio Fiorino; Letizia Bacchi-Reggiani; Dario de Biase; Adele Fornelli; Michele Masetti; Andrea Tura; Fabio Grizzi; Matteo Zanello; Laura Mastrangelo; Raffaele Lombardi; Giorgia Acquaviva; Luca di Tommaso; Arrigo Bondi; Michela Visani; Sergio Sabbatani; Laura Pontoriero; Carlo Fabbri; Andrea Cuppini; Annalisa Pession; Elio Jovine
Journal:  World J Gastroenterol       Date:  2015-12-07       Impact factor: 5.742

5.  Etiological factors in primary hepatic B-cell lymphoma.

Authors:  Kanta Kikuma; Jiro Watanabe; Yumi Oshiro; Tatsuo Shimogama; Yumi Honda; Seiichi Okamura; Koichi Higaki; Naokuni Uike; Tetsuro Soda; Seiya Momosaki; Tadaaki Yokota; Satoshi Toyoshima; Morishige Takeshita
Journal:  Virchows Arch       Date:  2012-03-07       Impact factor: 4.064

6.  Chronic hepatitis virus infection in patients with multiple myeloma: clinical characteristics and outcomes.

Authors:  Chung-Jen Teng; Han-Tsung Liu; Chun-Yu Liu; Chi-Hsiu Hsih; Jih-Tung Pai; Jyh-Pyng Gau; Jin-Hwang Liu; Tzeon-Jye Chiou; Hui-Chi Hsu; Po-Min Chen; Cheng-Hwai Tzeng; Yuan-Bin Yu
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

7.  Hepatitis-C Infection Incidence Among the non-Hodgkin's B-cell Lymphoma Patients in the Northeast of Iran.

Authors:  Seyed Amir Aledavood; Mohammad Reza Ghavam-Nasiri; Kamran Ghaffarzadegan; Hamid Reza Raziee; Golnaz Saboori; Kazem Anvari; Samira Mohtashami; Mitra Ahadi; Bahram Memar
Journal:  Iran J Cancer Prev       Date:  2014

8.  Changes in hepatitis C virus antibody titer and viral RNA load in non-Hodgkin's lymphoma patients after rituximab chemotherapy.

Authors:  Y Tsutsumi; K Ichiki; S Shiratori; T Kawamura; J Tanaka; M Asaka; M Imamura; N Masauzi
Journal:  Int J Lab Hematol       Date:  2008-02-14       Impact factor: 2.877

9.  In Situ Hepatitis C NS3 Protein Detection Is Associated with High Grade Features in Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas.

Authors:  Danielle Canioni; Jean-Marie Michot; Pascaline Rabiega; Thierry J Molina; Frédéric Charlotte; Thierry Lazure; Frédéric Davi; Catherine Settegrana; Françoise Berger; Laurent Alric; Patrice Cacoub; Benjamin Terrier; Felipe Suarez; David Sibon; Jehan Dupuis; Cyrille Feray; Hervé Tilly; Stanislas Pol; Bénédicte Deau Fischer; Sandrine Roulland; Catherine Thieblemont; Véronique Leblond; Fabrice Carrat; Olivier Hermine; Caroline Besson
Journal:  PLoS One       Date:  2016-06-03       Impact factor: 3.240

10.  Evaluation of HBV, HCV, and HIV seroprevalence in patients with plasma cell disorders.

Authors:  Duygu Mert; Alparslan Merdin; Merih Kizil Çakar; Mehmet Sinan Dal; Fevzi Altuntaş
Journal:  Medicine (Baltimore)       Date:  2020-08-21       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.